Lv2
180 积分 2022-04-24 加入
Olutasidenib in recurrent/relapsed locally advanced or metastatic IDH1-mutated chondrosarcoma: phase 1b/2 trial
28天前
已完结
Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (HARMONi-6): a randomised, double-blind, phase 3 trial
1个月前
已完结
Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (HARMONi-6): a randomised, double-blind, phase 3 trial
1个月前
已完结
Management of patients with higher-risk myelodysplastic syndromes after failure of hypomethylating agents: What is on the horizon?
2个月前
已完结
Menin inhibitors for adult acute myeloid leukemia: 2025 update
2个月前
已完结
Treatment of Higher-Risk Myelodysplastic Syndromes After Failure of Hypomethylating Agents
2个月前
已完结
Efficacy and Safety of Obinutuzumab in Active Systemic Lupus Erythematosus
3个月前
已完结
Elucidating the risk factors and oncogene drivers of acute myeloid leukemia
3个月前
已完结
Therapeutic horizon of acute myeloid leukemia: Success, optimism, and challenges
3个月前
已完结
Recent developments in myeloid immune modulation in cancer therapy
3个月前
已完结
皖公网安备34019202002308
